18 GHP / International Life Science Awards 2018 , Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.2 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through GHB17002 Frazier Healthcare Partners Adds Two Experienced Professionals to Life Sciences Team Frazier Healthcare Partners has announced the addition of two new members to its Life Sciences team: Tracy Saxton, Ph.D. as an Entrepreneur-in-Residence (EIR), andVanessa Bhark as a Senior Associate. innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. Joining them, Dr. Saxton, an EIR will focus on company creation efforts. She is the founder and CEO of Aucupo Biosciences, a newly formed Frazier search company focused on identifying novel therapeutics for patients with unmet medical need. Prior to joining Frazier, Dr. Saxton held investment positions with Pivotal bioVenture Partners, the Roche Venture Fund (RVF) and SV Life Sciences Advisers (SVLSA), where she focused on the biopharmaceutical sector. Dr. Saxton previously held positions at Tularik (acquired by Amgen) and Threshold Pharmaceuticals. She began her career as a drug discovery scientist and moved to leadership roles in Regulatory Affairs, Clinical Development and Project Management. As a Senior Associate, Ms. Bhark will focus on evaluating investments and creating new ventures in life sciences. Prior to joining Frazier, she was in Corporate Development at Gilead Sciences, where she structured and led the negotiation of licenses, collaborations, and acquisitions across therapeutic areas. Previously, Ms. Bhark was a Business Development Manager at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where she led the evaluation and recommendation of licensing and acquisition opportunities for Janssen’s $3.2 billion Infectious Disease Franchise. In addition, she worked for Morgan Stanley in the Equity Research Division with a focus on public biotech investments. “We are excited to have Tracy and Vanessa join our team; collectively, they bring significant skill sets in venture, drug development, and business development to the life sciences venture group,” said Jamie Topper, M.D., Ph.D., Managing General Partner with the Frazier Life Sciences team.